肺心病合并冠心病90例临床治疗

目的总结异舒吉联合依拉普利治疗肺心病合并冠心病的疗效。方法对照组均给予平喘、氧疗、止咳以及祛痰治疗,同时给予强心利尿及抗感染治疗,扩张患者的冠状动脉,对患者的心肺功能进行进一步的治疗。治疗组在对照组治疗的前提下,选择20～30mg的异舒吉针剂,同时添加500mL的葡萄糖液,葡萄糖液的浓度为5%,每天进行一次静脉滴注,一个疗程约10d左右。此外还应给予依拉普利治疗,其最初剂量约为5mg,每天需服用一次,1周后可以将剂量改为10mg,每天需服用一次,1个疗程为8周。结果对照组总有效率为73.80%,治疗组总有效率为95.74%,治疗组疗效明显优于对照组,存在统计学意义(P<0.05);治疗组PaCO2的下降效果更优于对照组,存在统计学意(P<0.05),同时治疗组PaO2的上升效果更优于对照组,存在统计学意(P<0.05)。结论异舒吉联合依拉普利治疗肺心病合并冠心病可取得满意的疗效,值得在临床医学中推广使用。

Pulmonary Heart Disease Complicated by Coronary Heart Disease Clinical Treatment of 90 Cases

Objectives To summarize the curative effect of isosorbide dinitrate combined with enalapril on the treatment of pulmonary heart disease combined with coronary heart disease.Methods The control group was given the treatment of asthma,oxygen therapy,antitussive and expectorant and the treatment of strong heart diuresis and anti infection.Expanding coronary artery of patients and giving further treatment on heart and lung function of patients.On the basis of the treatment of the control group,the treatment group is given 20~30mgisoket injection adding 500mL glucose liquid whose concentration is 5%.An intravenous drip was given everyday,a course is about 10 days.In addition,enalapril should be given to treat and the initial dose is about 5mg,which was taken 1 times everyday.Dose can be 10mg after 1 week,1 times everyday and a course is about 8 weeks.Results Total efficiency of the control group was 73.80% and total efficiency of the treatment group was 95.74%.The curative effect of the treatment group was better significantly than the control group,which had statistical significance（P0.05）.The decline effect of PaCO2 in the treatment group was better than the control group,which had statistical significance（P0.05）.And the increasing effect of PaO2 in the treatment group was better than the control group,which had statistical significance（P0.05）.Conclusion Isosorbide dinitrate combined with enalapril in treatment of pulmonary heart disease combined with coronary heart disease can get satisfactory effect,which is worthy of promotion and application in clinical application.